Clinical Trials
32 trialsNCT03246906 2026-05-14
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT03514017 2026-03-02
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT01997840 2025-03-04
ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma
Celgene
Phase 1/2 Terminated
NCT03582033 2024-12-24
A Safety Study of SEA-BCMA in Patients With Multiple Myeloma
Seagen Inc.
Phase 1 Terminated
NCT04310592 2024-12-12
CYNK001AML01
Celularity Incorporated
Phase 1 Terminated
NCT02978235 2024-09-05
A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma
Taiho Oncology, Inc.
Phase 1 Terminated
NCT05641324 2024-02-12
A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
Anaveon AG
Phase 1 Terminated
NCT05828654 2023-10-12
Intervention to Address Psychosocial Needs Among Socially Disadvantaged Older Adults With Cancer
UNC Lineberger Comprehensive Cancer Center
Phase NA Terminated
NCT05351866 2023-08-04
Digital Therapeutic for Adolescent Depressive Symptoms in Hematology, Oncology, and Weight Management
Limbix Health, Inc.
Phase NA Terminated
NCT02452983 2022-06-02
SS1
Baylor College of Medicine
Phase 1 Terminated
NCT03287245 2021-12-08
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera
Hoffmann-La Roche
Phase 2 Terminated
NCT02627677 2021-11-26
OPTIC-2L
Takeda
Phase 3 Terminated
NCT02055781 2021-11-18
PAC326
CTI BioPharma
Phase 3 Terminated
NCT00113802 2021-08-19
Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia
Gilead Sciences
Phase 2 Terminated
NCT03037645 2020-10-19
Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers
Sunesis Pharmaceuticals
Phase 1/2 Terminated
NCT01773187 2020-09-29
Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
CTI BioPharma
Phase 3 Terminated
NCT01998828 2020-04-20
Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia
Sierra Oncology LLC - a GSK company
Phase 2 Terminated
NCT03195010 2019-10-21
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT02592876 2019-05-17
Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma
Seagen Inc.
Phase 2 Terminated
NCT02855359 2019-03-11
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Seagen Inc.
Phase 2 Terminated
NCT02641002 2018-10-18
A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)
Celgene
Phase 1 Terminated
NCT01924169 2018-09-20
Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01925612 2018-06-21
Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Seagen Inc.
Phase 2 Terminated
NCT01220297 2017-06-05
Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT
Stanford University
Phase 2 Terminated
NCT01191749 2017-05-09
Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00579111 2016-05-04
Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)
Baylor College of Medicine
Phase 1/2 Terminated
NCT01359254 2015-04-30
Cord Blood Transplantation for Patients With Cancer
University of Chicago
Phase 2 Terminated
NCT00529503 2015-02-25
A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL
Seagen Inc.
Phase 2 Terminated
NCT00649584 2014-12-18
A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies
Seagen Inc.
Phase 1 Terminated
NCT01650805 2014-11-17
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Ariad Pharmaceuticals
Phase 3 Terminated
NCT00074763 2012-08-02
Comparing Fresh Random Platelets and Autologous Cryopreserved Thrombosol Treated Autologous Platelets
M.D. Anderson Cancer Center
Phase 3 Terminated
NCT00790452 2011-12-08
Aspirin Prophylaxis for Venous Thromboembolism in Glioblastoma
M.D. Anderson Cancer Center
Phase 2 Terminated